Literature DB >> 26462129

Chemotherapy: Limited use of the intraperitoneal route for ovarian cancer-why?

Maurie Markman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26462129     DOI： 10.1038/nrclinonc.2015.177

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: a systematic review.

Authors:  Clarisse Eveno; Marc Pocard
Journal:  Pleura Peritoneum       Date:  2017-01-10

2.  Preclinical study of CC223 as a potential anti-ovarian cancer agent.

Authors:  Zhenzhen Jin; Huanfu Niu; Xuenan Wang; Lei Zhang; Qin Wang; Aijun Yang
Journal:  Oncotarget       Date:  2017-05-10

3.  Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study.

Authors:  Florian Kurtz; Florian Struller; Philipp Horvath; Wiebke Solass; Hans Bösmüller; Alfred Königsrainer; Marc A Reymond
Journal:  Gastroenterol Res Pract       Date:  2018-10-24       Impact factor: 2.260

4.  Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Authors:  Koen P Rovers; Robin J Lurvink; Emma Ce Wassenaar; Thomas Jm Kootstra; Harm J Scholten; Rudaba Tajzai; Maarten J Deenen; Joost Nederend; Max J Lahaye; Clément Jr Huysentruyt; Iris van 't Erve; Remond Ja Fijneman; Alexander Constantinides; Onno Kranenburg; Maartje Los; Anna Mj Thijs; Geert-Jan M Creemers; Jacobus Wa Burger; Marinus J Wiezer; Djamila Boerma; Simon W Nienhuijs; Ignace Hjt de Hingh
Journal:  BMJ Open       Date:  2019-07-27       Impact factor: 2.692

5.  BRDT promotes ovarian cancer cell growth.

Authors:  Ling Chen; Shang Cai; Jing-Mei Wang; Ying-Ying Huai; Pei-Hua Lu; Qian Chu
Journal:  Cell Death Dis       Date:  2020-11-30       Impact factor: 8.469

6.  Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences.

Authors:  Yuanming Shen; Sangsang Tang; Junfen Xu; Xing Xie; Zhongbo Chen
Journal:  Front Med (Lausanne)       Date:  2022-03-17

7.  Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Authors:  Maria Quanz; Urs B Hagemann; Sabine Zitzmann-Kolbe; Beatrix Stelte-Ludwig; Sven Golfier; Cem Elbi; Dominik Mumberg; Karl Ziegelbauer; Christoph A Schatz
Journal:  Oncotarget       Date:  2018-09-25

8.  Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.

Authors:  Tingyan Shi; Rong Jiang; Jinjin Yu; Huijuan Yang; Dongsheng Tu; Zhiyuan Dai; Yang Shen; Yuqin Zhang; Xi Cheng; Huixun Jia; Ruiqin Tu; Huaying Wang; Jie Tang; Yuting Luan; Shumo Cai; Rongyu Zang
Journal:  Br J Cancer       Date:  2018-06-14       Impact factor: 7.640

9.  Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.

Authors:  Chen-Yu Huang; Min Cheng; Na-Rong Lee; Hsin-Yi Huang; Wen-Ling Lee; Wen-Hsun Chang; Peng-Hui Wang
Journal:  Int J Environ Res Public Health       Date:  2020-03-26       Impact factor: 3.390

10.  A real-time ex vivo model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models.

Authors:  Iaroslav Sautkin; Wiebke Solass; Frank-Jürgen Weinreich; Alfred Königsrainer; Martin Schenk; Karolin Thiel; Marc A Reymond
Journal:  Pleura Peritoneum       Date:  2019-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.